Could a New Weight Loss Approach Have Longer Term Benefits than GLP-1s?

The episode opens with Vincent Marion explaining why adipose tissue, not liver or muscle, sits at the heart of insulin resistance. Although fat cells handle only about 10 % of circulating glucose, their ability to switch to lipid‑only metabolism releases toxic lipids that drive whole‑body insulin resistance and accelerate aging. Marion also highlights growing safety concerns around GLP‑1 agonists, which, while powerful for weight loss, can trigger up to 40 % of lost weight as muscle, raising questions about long‑term metabolic durability. These insights push researchers to explore adipose‑centric therapies that could overcome the muscle‑loss drawback of current treatments.

Marion then introduces PATAS, a peptide that mimics insulin’s effect on a specific ALMS1‑αPKC interaction in diseased adipocytes. By breaking this protein‑protein link, PATAS re‑activates glucose uptake in fat cells, restoring normal lipid signaling and improving systemic insulin sensitivity. Pre‑clinical models in mice, rats and dogs showed reversal of fatty‑liver disease, reduced fibrosis, and a restored muscle lipid ratio that made muscle tissue more resistant to catabolism. Importantly, the muscle‑protective effect appears independent of weight change, suggesting a direct signaling benefit.

Finally, Marion positions PATAS as a first‑in‑class insulin sensitizer that could sit alongside GLP‑1 agents rather than replace them. With phase 1A trials in healthy volunteers completed and phase 1B/2 studies in type 2 diabetes slated, the company aims to demonstrate complementary benefits—weight loss from GLP‑1s plus preserved muscle and improved glucose control from PATAS. As patents on semaglutide expire worldwide, the market will see cheaper GLP‑1 options, making a differentiated, muscle‑sparing therapy an attractive proposition for clinicians and payers seeking durable metabolic solutions. If successful, PATAS could open a new therapeutic class focused on adipocyte function, reshaping the metabolic disease landscape.